Catalyst Watch – Vol. 2, Edition 12 (4/18/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

High Cash / Share Stocks in Biotech (Part I)

Due to the sector sell-off in biotech, I thought it may be interesting to provide subscribers a list of high net cash per share stocks (basically cash and equivalents less.

Catalyst Watch – Vol. 2, Edition 11 (4/11/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 10 (4/4/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 9 (3/28/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 8 (3/18/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 7 (3/12/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Week’s Option Activity (2/20 ~ 3/04)

The following stocks had notable activity in their options during the past week(s): $CYTK (2/20): There were two large trades – one bullish and one bearish. (1) Bullish: 2,900 MAY.

Catalyst Watch – Vol. 2, Edition 6 (3/4/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 5 (2/25/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Week’s Option Activity (2/04 ~ 2/19)

The following stocks had notable activity in their options during the past week(s): $ARRY (2/4): 2,000 JUN 5.0 strike Puts were sold to open (stock at $4.52) against the purchase.

Catalyst Watch – Vol. 2, Edition 4 (2/11/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 3 (2/3/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Week’s Option Activity (1/13 ~ 1/28)

The following stocks had notable activity in their options during the past week(s): $XOMA (1/13): 2,550 JUN risk reversals were purchased (stock at $8.32) for 0.40 or $102,000. 2,550 JUN.

Catalyst Watch – Vol. 2, Edition 2 (1/24/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Catalyst Watch – Vol. 2, Edition 1 (1/14/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Week’s Option Activity (12/27 ~ 1/9)

The following stocks had notable activity in their options during the past week(s): $GERN (12/27): 663 JUN 5.0 strike Calls (stock at $5.10) were purchased for 1.40 or total cost.

Catalyst Watch – Vol. 1, Edition 11 (12/31/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (12/11~12/20)

The following stocks had notable activity in their options during the past week(s): $ARRY (12/11): 3,500 DEC/MAR 5.0 strike Put Time spreads (stock at $5.09) were sold for a net.

Catalyst Watch – Vol. 1, Edition 10 (12/13/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (12/2~12/9)

The following stocks had notable activity in their options during the past week: $XOMA (12/2): 2,000 MAR 5.0 Strike Calls (stock at $4.78) were purchased for 1.30 or $260,000 total.

Catalyst Watch – Vol. 1, Edition 9 (12/4/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (11/18~11/21)

The following stocks had notable activity in their options during the past week(s): $HZNP (11/18): 1,632 FEB14 6.0 strike Calls (stock at $4.47) were purchased for 0.95 or $155,040. Buyer.

Catalyst Watch – Vol. 1, Edition 8 (11/20/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names.  Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (11/6~11/13)

The following stocks had notable activity in their options during the past week(s): $MACK (11/6): 600 MAR14 2.50 strike (stock at $2.28) Calls were purchased for 0.60 or $36,000 –.

Catalyst Watch – Vol. 1, Edition 7 (11/12/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (10/31~11/4)

The following stocks had notable activity in their options during the past week(s): $VNDA (10/31): Lots of activity – we will stick to the bigger trades. 1,000 NOV 4.0 strike.

Catalyst Watch – Vol. 1, Edition 6 (10/30/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Catalyst Watch – Vol. 1, Edition 5 (10/22/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Week’s Option Activity (10/10~10/16)

The following stocks had notable activity in their options during the past week(s): $XOMA (10/10): 3,000 OCT 5.0 strike Calls were bought (stock at $4.69) for 0.50 or $150,000. This.

Catalyst Watch – Vol. 1, Edition 4 (10/11/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

Browsing 31 / 152 articles